Your request to link to rcsb for JAK1/TYK2

• 3EYG: crystal structures of jak1 and jak2 inhibitor complexes 10-feb-09 3eyg 1 title (10.1016/J.JMB.2009.01.041 )
• 3EYH: crystal structures of jak1 and jak2 inhibitor complexes 10-feb-09 3eyh 1 title (10.1016/J.JMB.2009.01.041 )
• 3LXN: structural and thermodynamic characterization of the tyk2 and jak3 kinase domains in complex with cp-690550 and cmp-6 (10.1016/J.JMB.2010.05.020 )
• 3LXP: structural and thermodynamic characterization of the tyk2 and jak3 kinase domains in complex with cp-690550 and cmp-6 (10.1016/J.JMB.2010.05.020 )
• 3NYX: non-phosphorylated tyk2 jh1 domain with quinoline-thiadiazole- thiophene inhibitor (10.1002/PROT.22889 )
• 3NZ0: non-phosphorylated tyk2 kinase with cmp6 (10.1002/PROT.22889 )
• 3ZON: human tyk2 pseudokinase domain bound to a kinase inhibitor
• 4E1Z: structure of mouse tyk-2 complexed to a 3-aminoindazole inhibitor (10.1186/1472-6807-12-22 )
• 4E20: structure of mouse tyk-2 complexed to a 3-aminoindazole inhibitor (10.1186/1472-6807-12-22 )
• 4E4L: jak1 kinase (jh1 domain) in complex with compound 30 (10.1021/JM300438J )
• 4E4N: jak1 kinase (jh1 domain) in complex with compound 49 (10.1021/JM300438J )
• 4E5W: jak1 kinase (jh1 domain) in complex with compound 26 (10.1021/JM300438J )
• 4EHZ: the jak1 kinase domain in complex with inhibitor (10.1021/JM300628C )
• 4EI4: jak1 kinase (jh1 domain) in complex with compound 20 (10.1021/JM300628C )
• 4FK6: jak1 kinase (jh1 domain) in complex with compound 72 (10.1016/J.BMCL.2012.10.008 )
• 4GFO: tyk2 kinase (jh1 domain) with 2,6-dichloro-n-(2-oxo-2,5- dihydropyridin-4-yl)benzamide (10.1016/J.EJMECH.2013.03.070 )
• 4GIH: tyk2 (jh1) in complex with 2,6-dichloro-n-{2-[(cyclopropylcarbonyl) amino]pyridin-4-yl}benzamide (10.1016/J.EJMECH.2013.03.070 )
• 4GII: tyk2 (jh1) in complex with 2,6-dichloro-4-cyano-n-{2- [(cyclopropylcarbonyl)amino]pyridin-4-yl}benzamide (10.1021/JM400266T )
• 4GJ2: tyk2 (jh1) in complex with 2,6-dichloro-n-[2-({[(1r,2r)-2- fluorocyclopropyl]carbonyl}amino)pyridin-4-yl]benzamide (10.1021/JM400266T )
• 4GJ3: tyk2 (jh1) in complex with 2,6-dichloro-4-cyano-n-[2-({[(1r,2r)-2- fluorocyclopropyl]carbonyl}amino)pyridin-4-yl]benzamide (10.1021/JM400266T )
• 4GVJ: tyk2 (jh1) in complex with adenosine di-phosphate (10.1016/J.EJMECH.2013.03.070 )
• 4I5C: the jak1 kinase domain in complex with inhibitor (10.1016/J.BMCL.2013.04.018 )
• 4IVB: jak1 kinase (jh1 domain) in complex with the inhibitor trans-4-{2- [(1r)-1-hydroxyethyl]imidazo[4,5-d]pyrrolo[2,3-b]pyridin-1(6h)- yl}cyclohexanecarbonitrile (10.1021/JM4004895 )
• 4IVC: jak1 kinase (jh1 domain) in complex with the inhibitor (trans-4-{2- [(1r)-1-hydroxyethyl]imidazo[4,5-d]pyrrolo[2,3-b]pyridin-1(6h)- yl}cyclohexyl)acetonitrile (10.1021/JM4004895 )
• 4IVD: jak1 kinase (jh1 domain) in complex with compound 34 (10.1021/JM4004895 )
• 4K6Z: the jak1 kinase domain in complex with compound 37 (10.1016/J.BMCL.2013.08.082 )
• 4K77: jak1 kinase (jh1 domain) in complex with compound 6 (10.1016/J.BMCL.2013.08.082 )
• 4L00: crystal structure of the apo jak1 pseudokinase domain (10.1038/NSMB.2673 )
• 4L01: crystal structure of the v658f apo jak1 pseudokinase domain (10.1038/NSMB.2673 )
• 4OLI: the pseudokinase/kinase protein from jak-family member tyk2 (10.1073/PNAS.1401180111 )
• 4PO6: crystal structure of the human tyk2 ferm and sh2 domains with an ifnar1 intracellular peptide
• 4PY1: crystal structure of tyk2 in complex with compound 15, 6-((2,5- dimethoxyphenyl)thio)-3-(1-methyl-1h-pyrazol-4-yl)-[1,2,4]triazolo[4, 3-b]pyridazine (10.1016/J.BMCL.2014.07.052 )
• 4WOV: crystal structure of tyrosine kinase 2 jh2 (pseudo kinase domain) complexed with bms-066 aka 2-methoxy-n-({6-[3-methyl-7-(methylamino)- 3,5,8,10-tetraazatricyclo[7.3.0.0, 6]dodeca-1(9),2(6),4,7,11-pentaen- 11-yl]pyridin-2-yl}methy l)acetamide (10.1074/JBC.M114.619502 )
• 5C01: crystal structure of kinase (10.1074/JBC.M115.672048 )
• 5C03: crystal structure of kinase (10.1074/JBC.M115.672048 )
• 5E1E: human jak1 kinase in complex with compound 30 at 2.30 angstroms resolution (10.1016/J.BMCL.2015.11.031 )
• 5F1Z: structure of tyk2 with inhibitor 16: 3-azanyl-5-[(2~{s})-3- methylbutan-2-yl]-7-[1-methyl-5-(2-oxidanylpropan-2-yl)pyrazol-3-yl]- 1~{h}-pyrazolo[4,3-c]pyridin-4-one (10.1021/ACS.JMEDCHEM.5B01857 )
• 5F20: structure of tyk2 with inhibitor 4: 3-azanyl-5-(2-methylphenyl)-7-(1- methylpyrazol-3-yl)-1~{h}-pyrazolo[4,3-c]pyridin-4-one (10.1021/ACS.JMEDCHEM.5B01857 )
• 5HX8: jak1 complex with 4-[(4-aminocyclohexyl)amino]-3-(1h-benzimidazol-2- yl)-1h-pyridin-2-one (10.1016/J.BMCL.2016.02.035 )
• 5IXD: structure of human jak1 ferm/sh2 in complex with ifn lambda receptor (10.1016/J.STR.2016.03.023 )
• 5IXI: structure of human jak1 ferm/sh2 in complex with ifnlr1/il10ra chimera (10.1016/J.STR.2016.03.023 )
• 5KHW: crystal structure of jak1 in complex with adp (10.1107/S2053230X16016356 )
• 5KHX: crystal structure of jak1 in complex with pf-4950736 (10.1107/S2053230X16016356 )
• 5L04: structure of interferon lambda 1 receptor with human kinase jak1 (10.1016/J.JMB.2016.10.005 )
• 5TKD: crystal structure of tyrosine kinase 2 jh2 (pseudo kinase domain) complexed with 6-[(3,5-dimethylphe nyl)amino]-8- (methylamino) imidazo[1,2-b]pyridazine-3-carbo xamide (10.1039/C6MD00560H )
• 5WAL: identification of an imidazopyridine scaffold to generate potent and selective tyk2 inhibitors that demonstrate activity in an in vivo psoriasis model (10.1016/J.BMCL.2017.08.022 )
• 5WO4: jak1 complexed with compound 28 (10.1021/ACS.JMEDCHEM.7B01135 )
• 6AAH: crystal structure of jak1 in complex with peficitinib (10.1016/J.BMC.2018.08.005 )
• 6AAM: crystal structure of tyk2 in complex with peficitinib (10.1016/J.BMC.2018.08.005 )
• 6BBU: crystal structure of jak1 in complex with compound 25 (10.1021/ACS.JMEDCHEM.7B01598 )
• 6C7Y: crystal structure of inhibitory protein socs1 in complex with jak1 kinase domain (10.1038/S41467-018-04013-1 )
• 6DBK: tyk2 with compound 8 (10.1021/ACS.JMEDCHEM.8B00917 )
• 6DBM: tyk2 with compound 23 (10.1021/ACS.JMEDCHEM.8B00917 )
• 6DBN: jak1 with compound 23 (10.1021/ACS.JMEDCHEM.8B00917 )
• 6ELR: human jak1 kinase domain in complex with compound 7
• 6GGH: human jak1 kinase domain in complex with inhibitor
• 6HZU: human jak1 in complex with lasw1393 (10.1021/ACS.JMEDCHEM.9B00533 )
• 6N77: structure of the human jak1 kinase domain with compound 15 (10.1016/J.BMCL.2019.04.008 )
• 6N78: structure of the human jak1 kinase domain with compound 21 (10.1016/J.BMCL.2019.04.008 )
• 6N79: structure of the human jak1 kinase domain with compound 20 (10.1016/J.BMCL.2019.04.008 )
• 6N7A: structure of the human jak1 kinase domain with compound 39 (10.1016/J.BMCL.2019.04.008 )
• 6N7B: structure of the human jak1 kinase domain with compound 38 (10.1016/J.BMCL.2019.04.008 )
• 6N7C: structure of the human jak1 kinase domain with compound 56 (10.1016/J.BMCL.2019.04.008 )
• 6N7D: structure of the human jak1 kinase domain with compound 54 (10.1016/J.BMCL.2019.04.008 )
• 6NSL: crystal structure of tyrosine kinase 2 jh2 (pseudo kinase domain) complexed with compound-6c aka 6-((1-(4-cyanopheny l)-2-oxo-1,2- dihydro-3-pyridinyl)amino)-n-cyclopropyl-8-(m ethylamino)imidazo[1,2- b]pyridazine-3-carboxamide (10.1021/ACSMEDCHEMLETT.9B00035 )
• 6NZE: crystal structure of tyrosine kinase 2 jh2 (pseudo kinase domain) complexed with compound_5 aka 4-[(2-carbamoylphen yl)amino]-6-[(5- fluoropyridin-2-yl)amino]-n-methylpyridine -3-carboxamide (10.1021/ACS.JMEDCHEM.9B00443 )
• 6NZF: crystal structure of tyrosine kinase 2 jh2 (pseudo kinase domain) complexed with compound_5 aka 4-[(2-carbamoylphen yl)amino]-6-[(5- fluoropyridin-2-yl)amino]-n-methylpyridine -3-carboxamide (10.1021/ACS.JMEDCHEM.9B00443 )
• 6NZH: crystal structure of tyrosine kinase 2 jh2 (pseudo kinase domain) complexed with compound_40 aka 6-cyclopropaneamido-4-[(2- methanesulfonylphenyl)amino]-n-methylpyridine-3-carboxamide (10.1021/ACS.JMEDCHEM.9B00443 )
• 6NZP: crystal structure of tyrosine kinase 2 jh2 (pseudo kinase domain) complexed with compound-11 aka 6-cyclopropaneamido-4-{[2-methoxy-3- (1-methyl-1h-1,2,4-tri azol-3-yl)phenyl]amino}-n-(?h?) methylpyridazine-3-carboxamide (10.1021/ACS.JMEDCHEM.9B00444 )
• 6NZQ: crystal structure of tyrosine kinase 2 jh2 (pseudo kinase domain) complexed with compound_29 aka 6-[(5-fluoro-4-meth ylpyridin-2-yl) amino]-4-({2-methoxy-3-[(pyridin-2-ylmethyl )carbamoyl]phenyl}amino)- n-methylpyridine-3-carboxamide (10.1021/ACS.JMEDCHEM.9B00444 )
• 6NZR: crystal structure of tyrosine kinase 2 jh2 (pseudo kinase domain) complexed with compound_12 aka 4-[(2-methanesulfonylphenyl)amino]-n- (h3)methyl-6-[(pyridin-2- yl)amino]pyridazine-3-carboxamide (10.1021/ACS.JMEDCHEM.9B00444 )
• 6OVA: crystal structure of tyk2 with novel pyrrolidinone inhibitor (10.1016/J.BMCL.2020.126963 )
• 6RSB: structure based optimization of jak1-atp binding pocket inhibitors in the aminopyrazole class
• 6RSC: structure based optimization of jak1-atp binding pocket inhibitors in the aminopyrazole class
• 6RSD: structure based optimization of jak1-atp binding pocket inhibitors in the aminopyrazole class
• 6RSE: structure based optimization of jak1-atp binding pocket inhibitors in the aminopyrazole class
• 6RSH: structure based optimization of jak1-atp binding pocket inhibitors in the aminopyrazole class
• 6SM8: human jak1 kinase domain in complex with inhibitor (10.1021/ACS.JMEDCHEM.9B01392 )
• 6SMB: human jak1 kinase domain in complex with inhibitor (10.1021/ACS.JMEDCHEM.9B01392 )
• 6TPE: fragment-based discovery of pyrazolopyridones as jak1 inhibitors with excellent subtype selectivity (10.1021/ACS.JMEDCHEM.0C00359 )
• 6TPF: fragment-based discovery of pyrazolopyridones as jak1 inhibitors with excellent subtype selectivity (10.1021/ACS.JMEDCHEM.0C00359 )
• 6VNS: crystal structure of tyk2 kinase with compound 13 (10.1016/J.BMC.2020.115481 )
• 6VNV: crystal structure of tyk2 kinase with compound 14 (10.1016/J.BMC.2020.115481 )
• 6VNX: crystal structure of tyk2 kinase with compound 19 (10.1016/J.BMC.2020.115481 )
• 6VNY: crystal structure of tyk2 kinase with compound 10 (10.1016/J.BMC.2020.115481 )
• 6W8L: crystal structure of jak1 kinase with compound 10 (10.1016/J.BMC.2020.115481 )
• 6X8F: crystal structure of tyk2 with compound 11 (10.1021/ACS.JMEDCHEM.0C00948 )
• 6X8G: crystal structure of tyk2 with compound 22 (10.1021/ACS.JMEDCHEM.0C00948 )
• 7AX4: human tyk2 pseudokinase domain (575-869) in complex with 5-(4-fluoro- phenyl)-2-ureido-thiophene-3-carboxylic acid amide (10.1177/24725552211002472 )
• 7K7O: crystal structure of tyrosine kinase 2 jh2 (pseudo kinase domain) complexed with compound-12 aka:6-[(cyclopropanecarbonyl)amino]-4-{[2- methoxy-3-(pyrimidin-2-yl)phenyl]amino}-n-methylpyridazine-3- carboxamide (10.1021/ACS.JMEDCHEM.0C01698 )
• 7K7Q: crystal structure of tyrosine kinase 2 jh2 (pseudo kinase domain) complexed with compound-12 aka:6-[(cyclopropanecarbonyl)amino]-4-({3- [6-(dimethylcarbamoyl)pyridazin-3-yl]-2-methoxyphenyl}amino)-n- methylpyridazine-3-carboxamide (10.1021/ACS.JMEDCHEM.0C01698 )
• 7T6F: structure of active janus kinase (jak) dimer complexed with cytokine receptor intracellular domain (10.1126/SCIENCE.ABN8933 )